Singapore has one of the most advanced and innovative infrastructure in the Asia Pacific region. The Government of Singapore has identified the biotech industry as a future growth area contributing to the country’s overall development and thus, it has allocated a substantial budget to fund the industry. The country has increased its R&D budget from US$ 4 Billion during 2001-2005 to over two-folds to reach US$ 8 Billion during 2006-2010. Hence, Singapore’s biotechnology market is expected to grow at a CAGR of around 13% during 2010 - 2012, says our new research report “Asia Pacific Biotechnology Market (2008-2012)”.
This huge growth will stem from the strong infrastructure and favorable business environment. Some heavy investments by private sector firms will fuel the growth of the market. The small size and population of the country however, will be a major restraint and cause the industry to reach maturation sooner than the larger markets, such as Japan, China, India, South Korea, and Australia. Although strong intellectual property rights and sound manufacturing & IT skills along with other factors discussed in the report will drive the future growth of the industry.
The report has included country profiles of several countries, which are Japan, China, India, South Korea, Malaysia, Australia, New Zealand, Taiwan, and Singapore. For each of the country covered, growth drivers and government regulations have been discussed in detail in the report.
“Asia Pacific Biotechnology Market (2008-2012)” also provides information of the key competitors in each country’s biotech market along with their business information and areas of expertise. The report shows a highly concentrated structure of the market, with the top players dominating the market. It provides segment level analysis of the industry along with emerging trends that may shape up with the betterment of economic conditions. The research will help consultants, industry analysts, and vendors to get in-depth knowledge of the current, past, and future performance of the industry. The report provides an extensive research on the recent trends of the Asia Pacific biotech industry along with impartial analysis considering the impact of financial crisis on its performance.
For more information visit: http://www.rncos.com/Report/IM138.htm |
